Neurology Central

Alemtuzumab shows strong results in 10 year follow-up

Research to be presented today at the American Academy of Neurology (AAN) 68th Annual Meeting (Vancouver, BC, Canada, 15–21 April 2016) will reveal a long-term analysis detailing 10 years of clinical efficacy of alemtuzumab (Lemtrada®) in patients with relapsing-remitting multiple sclerosis (RRMS).

The presentation discusses the results of the ongoing, long-term extension study of the Phase 2 CAMMS223 trial which recruited individuals with RRMS who had not previously been treated for the disease.

Alemtuzumab is a humanized monoclonal antibody therapy, selectively targeting the protein CD52 on B and T cells. Treatment results in a reduction in the numbers of circulating T and B cells, which are thought to play a key role in the inflammatory processes involved in multiple sclerosis.

More than 1500 patients have participated in trials of alemtuzumab and 900 have received the active substance, which was administered over a maximum of three separate courses.

Findings indicate that after 10 years of follow-up, 76% of participants were free from 6-month confirmed disability worsening (increase of ≥1.0 Expanded Disability Status Scale(EDSS) point [or ≥1.5 points if baseline EDSS=0]), 78% had an EDSS score which was stable, greater or equal to one point improvement in EDSS vs baseline. In addition to these results, a low annualized relapse rate of 0.08 was maintained.

Alasdair Coles (University of Cambridge, UK) commented: “These data provide further evidence of the long term response with Lemtrada in treatment-naïve patients with RRMS. It is remarkable that such infrequent dosing with Lemtrada offers stability or improvement of disability over ten years.”

Peter Kuiper from Sanofi Genzyme (UK) remarked: “We are very pleased with these new data, which are part of our extensive clinical development programme and our commitment to the field of MS.”

Source: Coles et al. Durable Efficacy of Alemtuzumab Over 10 Years: Long-term Follow-up of Patients With RRMS From the CAMMS223 Study. American Academy of Neurology (AAN) Annual Meeting 2016. Poster presentation P3 053.